Subscribe
F096 Why can we be optimistic about the vaccine development for COVID-19? (Glen de Vries, Medidata)

Faces of Digital Health

F096 Why can we be optimistic about the vaccine development for COVID-19? (Glen de Vries, Medidata)

August 28, 2020

F096 Why can we be optimistic about the vaccine development for COVID-19? (Glen de Vries, Medidata)

Glen de Vries is president of Medidata, the world’s largest platform for clinical research trial data. Medidata is working with several research groups working on the COVID-19 vaccine, including messenger RNA based vaccines in development by Moderna, which was the first vaccine in human clinical trials already in March. The third phase, with 30.000 participants from the US, began end of July. Glen talked about why we have reasons to be optimistic in vaccine development for COVID-19; he also shared some insight into his new book The Patient Equation and explained why clinical trials are complicated and how is technology from platforms to AI helping accelerate trial development and data analysis.

 

 

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
The Genome Files: How #bigdata Tailors Treatment Precision (personalized) medicine takes the guesswork out of treatment, and it all begins with a single data point. Studying one to understand all.